Medtronic Plc (NYSE:MDT) reported third-quarter 2025 sales of $8.29 billion, missing the consensus of $8.32 billion. The ...

Medtronic PLC (MDT) reports robust revenue and EPS growth, driven by innovations in Cardiac Ablation and Leadless Pacing, ...

Medtronic (MDT) stock slips as the company reaffirms full-year outlook after delivering mixed financial for Q3 fiscal 2025.

Q3 2025 Earnings Call Transcript February 18, 2025 Medtronic plc beats earnings expectations. Reported EPS is $1.39, ...

Reports Q3 revenue $8.29B, consensus $8.33B. “We delivered strong earnings this quarter, with significant improvements in both our gross margin ...

Medtronic's stock has been static, not delivering any gains for investors. Click here to find out why MDT stock is a Buy.

The medical device company posted revenue of $8.29 billion in the period, falling short of Street forecasts. Ten analysts surveyed by Zacks expected $8.33 billion. Medtronic expects full-year earnings ...

Medtronic stock was down stock was down today after its third-quarter revenue slightly missed the Wall Street analyst consensus.

Shares of Medtronic ( MDT -6.63%) were sinking 7.3% as of 11:21 a.m. ET on Tuesday. The decline came after the medical device ...

Medtronic's Q3 adjusted EPS of $1.39 surpassed forecasts by $0.03. Revenue of $8.29 billion fell short of expectations by $40 million. Premarket trading saw a 4.48% drop in Medtronic's stock price.

Medtronic (NYSE: MDT) recently announced its Q3 fiscal 2025 results (fiscal ends in April), reporting revenue of $8.29 billion, slightly below the $8.33 billion consensus estimate. Adjusted ...